Results 71 to 80 of about 7,978,447 (307)
Treatment effect estimates for major adverse cardiovascular events (MACE).
Treatment effect estimates for major adverse cardiovascular events (MACE).
Théodora Bejan-Angoulvant (2147893) +15 more
core +1 more source
The Gut–Heart Axis in Systemic Sclerosis: Evidence From a Large Prospective Early Disease Cohort
Objective Cardiac involvement significantly impacts prognosis in systemic sclerosis (SSc), highlighting the need for early risk stratification. Gastrointestinal (GI) symptoms are common and often manifest early. Emerging data suggest a link between GI and cardiac manifestations, possibly through shared mechanisms like dysautonomia.
Francesca R. Di Ciommo +9 more
wiley +1 more source
Background Cardiovascular outcome trials (CVOTs) are conducted on a background of standard of care including metformin. These analyses sought to determine whether the cardiovascular (CV) effects of semaglutide and other glucagon-like peptide-1 receptor ...
Mansoor Husain +5 more
doaj +1 more source
Perioperative Major Adverse Cardiovascular and Cerebrovascular Events Associated With Noncardiac Surgery [PDF]
Major adverse cardiovascular and cerebrovascular events (MACCE) are a significant source of perioperative morbidity and mortality following noncardiac surgery.To evaluate national trends in perioperative cardiovascular outcomes and mortality after major noncardiac surgery and to identify surgical subtypes associated with cardiovascular events using a ...
Nathaniel R, Smilowitz +5 more
openaire +2 more sources
a. Type 1 diabetes, b. Type 2 diabetes, c. Non-diabetes, d. Overall MACE, major adverse cardiovascular event. eGFR, estimated glomerular filtration rate.
Thomas R. Berni (7321634) +7 more
core +1 more source
Objective JAK inhibitors (JAKi) have shown promising effects in early‐phase studies of systemic sclerosis (SSc). We aimed to assess the safety and explore the effectiveness of JAKi compared to conventional immunosuppressants in SSc. Methods A longitudinal retrospective study of the European Scleroderma Trials and Research Group (EUSTAR) cohort was ...
Stefano Di Donato +27 more
wiley +1 more source
BackgroundIn a previous study, we found that a biomarker risk score (BRS) comprised of C‐reactive protein, fibrin‐degradation products, and heat shock protein‐70 predicts risk of myocardial infarction and death in coronary artery disease patients.
Nima Ghasemzadeh +7 more
doaj +1 more source
Abbreviations: PAF, paroxysmal atrial fibrillation; SEE, systemic embolic events; MACNE, major adverse cardiovascular or neurological events.
Takenori Yamaguchi (9606963) +17 more
core +1 more source
Objective Despite guideline recommendations, long‐term glucocorticoid (GC) use is common in rheumatoid arthritis (RA). We conducted a clinician survey nested within a large registry to identify patient and clinician factors associated with GC use. Methods Clinicians contributing patients to the CorEvitas Rheumatoid Arthritis Registry were surveyed ...
Michael D. George +7 more
wiley +1 more source
Background Cardiovascular diseases (CVDs) remain the leading cause of morbidity and mortality in end-stage kidney disease patients, with persistently high rates of major adverse cardiovascular events (MACEs). Traditional risk factors such as diabetes and
Chung-Kuan Wu +5 more
doaj +1 more source

